Cancer cells often exploit immune checkpoint pathways to evade immune surveillance. By upregulating checkpoint proteins like CTLA-4, tumors can inhibit the activation and proliferation of cytotoxic T cells, which are essential for targeting and killing cancer cells. Consequently, CTLA-4 becomes a strategic target for cancer immunotherapy.
